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Background: Mucopolysaccharidoses (MPSs) are rare genetic diseases caused by a deﬁcient activity of
one of the lysosomal enzymes involved in the glycosaminoglycan (GAG) breakdown pathway. These
metabolic blocks lead to the accumulation of GAGs in various organs and tissues, resulting in a multi-
systemic clinical picture. The pathological GAG accumulation begins a cascade of interrelated responses:
metabolic, inﬂammatory and immunological with systemic effects. Metabolic inﬂammation, secondary
to GAG storage, is a signiﬁcant cause of osteoarticular symptoms in MPS disorders.
Objective and method: The aim of this review is to present recent progress in the understanding of the
role of inﬂammatory and immune processes in the pathophysiology of osteoarticular symptoms in MPS
disorders and potential therapeutic interventions based on published reports in MPS patients and studies
in animal models.
Results and conclusions: The immune and skeletal systems have a number of shared regulatory molecules
and many relationships between bone disorders and aberrant immune responses in MPS can be
explained by osteoimmunology. The treatment options currently available are not sufﬁciently effective in
the prevention, inhibition and treatment of osteoarticular symptoms in MPS disease. A lot can be learnt
from interactions between skeletal and immune systems in autoimmune diseases such as rheumatoid
arthritis (RA) and similarities between RA and MPS point to the possibility of using the experience with
RA in the treatment of MPS in the future. The use of different anti-inﬂammatory drugs requires further
study, but it seems to be an important direction for new therapeutic options for MPS patients.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Mucopolysaccharidoses (MPSs) are a group of 11 inherited,
genetically conditioned, metabolic, more pronounced in connective
tissue disorders, with systemic and progressive course.
The most typical description includes characteristic facial fea-
tures, cardiac, pulmonary, neurological, ophthalmic and auditorys to: V. Opoka-Winiarska,
tology, Medical University of
30141.
: A. Jurecka, Department of
titute, Al. Dzieci Polskich 20,
228157489.
poka-Winiarska), ajurecka@
s Research Society International. Psymptoms, hepatosplenomegaly, abdominal and/or inguinal her-
nia, early accelerated growth and later growth retardation1e6. The
occurrence of musculoskeletal symptoms is characteristic for all
types of the disease, except for MPS III.
Skeletal abnormalities are associated with storage of glycos-
aminoglycans (GAGs) such as dermatan sulfate (DS), chondroitin
sulfate (CS) or keratan sulfate (KS), while storage of heparan sulfate
(HS) is associated central nervous system pathology7.
Joint stiffness and contractures might be found, except for MPS
IV in which there is joint laxity. Other major osteoarticular mani-
festations of MPS are claw hands, thoracolumbar kyphosis, scoli-
osis, odontoid hypoplasia, hip dysplasia, genu valgum and pectus
carinatum. Characteristic bone changes in imaging studies are
deﬁned as dysostosis multiplex (Fig. 1)8.
Clinical symptoms observed in patients with MPS are a conse-
quence of a deﬁcient activity of lysosomal enzymes that leads toublished by Elsevier Ltd. All rights reserved.
Fig. 1. Metabolic inﬂammation in MPS disease. IL-1 e interleukin 1b
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tion of GAGs is the beginning of a cascade of interrelated responses:
metabolic, inﬂammatory, and immunological with systemic effects9.
The immune and skeletal systems have a number of shared
regulatory molecules, including cytokines, receptors, signaling
molecules, and transcription factors. Recognition of the complex
interactions between the immune system and bone led to the
development of the interdisciplinary research ﬁeld osteoimmu-
nology, which aims to understand the molecular mechanisms be-
tween the skeletal and immune systems10e13.
The aim of this review is to present recent progress in the un-
derstanding of the role of inﬂammatory and immune processes in
the pathophysiology of osteoarticular symptoms in MPS disorders.
In order to develop new effective therapeutic strategies for MPS
disease, attention should be paid to the relationship between bone
disorders and aberrant immune responses.
Metabolic inﬂammation in MPS diseases (Fig. 1)
GAGs interact with a wide range of proteins involved in physi-
ological and pathological processes, including chemokines, cyto-
kines, growth factors, morphogens, enzymes, and adhesion
molecules14.
GAGs might induce inﬂammation in different cells. Simonaro
et al. demonstrated that in normal chondrocytes of healthy rats, DS
might stimulate nitric oxide (NO) release from and elicit apoptosis
effects on chondrocytes15. Wang et al. showed that administration
of GAGs such as hyaluronic acid, HS and CS A, B, and C to normal
mice induces signs of inﬂammation: arthritis, tendosynovitis,
dermatitis, and cellular inﬁltrates in various connective tissues16.
Circulating or locally released GAGs induced the clonal expansion of
various cells include lymphocytes T, lymphocytes B, and macro-
phages. These ﬁndings indicate that immunization against self-
antigens like GAGs alters the immune system and causes sys-
temic chronic inﬂammation disorder16.
Immune response and metabolic regulation are highly integrated
and the proper function of each is dependent on the other17e19.
Hotamisligil proposed a term “metaﬂammation” (metabolically trig-
gered inﬂammation) for a conditionprincipally triggered by nutrients
and, engaging a similar set of molecules and signaling pathways tothose involved in classical inﬂammation17. The long-term conse-
quences of prolonged inﬂammation are often not beneﬁcial and in
many disorders normal immune response is turned into a permitting
process leading to damage. In metabolic inﬂammation in MPS, the
factor that induces an immune process is ametabolic surplus of GAGs.
DiRosario et al. study of MPS IIIB mouse brain demonstrated
signiﬁcant up-regulation of numerous immune-related genes of
innate and adaptive immune cells and molecules, including T cells,
B cells, complement, immunoglobulin, Toll-like receptors (TLR),
and molecules essential for antigen presentation20. Killedar et al.
showed that lymphocytes from MPS IIIB mice transferred to naïve
mice cause neuroinﬂammation with increased expression of
proinﬂammatory cytokines and lymphocyte inﬁltration21.
Tessitore et al. as well as Simonaro et al. demonstrated that the
loss of degradation and recycling of GAGs results in an imbalance of
cellular homeostasis, reduces functionality of lysosomes with im-
pairs autophagy, accumulation of polyubiquitinated proteins and
mitochondrial function in MPS VI human ﬁbroblasts leading to
overproduction of reactive oxygen species22,23.
Osteoimmunological aspects of osteoarticular disorder in
MPS
Synovial inﬂammation
The synovial membrane in animals and patients with MPS VI
and VII shows characteristics of hyperplasia. Studies demonstrated
thatMPS VI and VII animals’ synovial cells proliferate at a faster rate
than normal cells15,23,24. No apoptosis was observed in these cells
(in contrast to MPS chondrocytes). Hyperproliferation could result
indirectly from increased levels of tumor necrosis factor (TNF)-
alpha and interleukin (IL)-1 and elevated levels of the prosurvival
lipid S1P. Levels of these cytokines are also markedly elevated in
synovial ﬂuid animals with MPS VI and VII25.
Articular and growth cartilages disorder
Growth and bone remodeling in MPS
Articular and growth cartilage is the main place of pathology in
the osteoarticular system in MPS25. Studies in MPS VI and VII
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growth cartilage. This inﬂammation has many similarities to the
process in rheumatoid arthritis (RA) (Table I). Simonaro et al.
demonstrated that culturedMPS VI rats’ chondrocytes release more
NO and TNF-alpha than normal cells and that GAGs might enhance
NO release. Importantly, Simonaro et al. showed that in MPS VI
animals, apoptosis of chondrocytes and the release of NO and TNF-
alpha increase with animals’ age. Chondrocytes’ impairment leads
to a depletion of cartilage matrix components causing future
articular destruction15.
Inﬂammatory cytokines have signiﬁcant impact on increased
apoptosis of chondrocytes and changes in matrix by up-regulation
of matrix metalloproteinase (MMP) gene expression, which was
demonstrated in animals with MPS VI and VII24. Despite increased
chondrocytes’ death, however, no signiﬁcant loss of their numbers
is observed, which is explained by increased expression of TGF-b,
an important growth factor in cell proliferation, including chon-
drocytes. Low content of osteonectin in the cartilage might indicate
that newly formed chondrocytes were not mature and could not
develop into bone. In MPS VI and VII animals’ chondrocytes the
levels of ceramide were also higher than in normal cells and this
was consistent with high levels of apoptosis in these cells25.
Cartilage matrix consists mostly of two organic extracellular
components: triple helical type II collagen and the proteoglycan,
aggrecan, which are synthesized by cartilage embedded chon-
drocytes. In arthritic diseases, cartilage can be attacked by various
proteases of the matrix MMPs and cysteine protease families (ca-
thepsins, CTs), which are constitutively expressed and induced
during disease development in chondrocytes, osteoclasts, synovial
ﬁbroblasts, and macrophages as well as in inﬁltrating leukocytes.
MMPs have been known to be primarily responsible for the carti-
lage matrix degradation. Typical collagenases in this protease
family are MMPs 1, 8, and 13. In RA, CTs and MMPs in synovial ﬁ-
broblasts and osteoclasts are prominently induced by inﬂammatory
cytokines such as TNF-alpha, IL-126.
An important role in the pathogenesis of MPS arthropathy plays
up-regulation of destructive enzymes such as matrix MMPs and
CTs. These enzymes degrade key components of the extracellular
matrix (ECM) including elastin, collagens and proteoglycans.
Elevation of destructive enzymes inMPSmay be due to induction of
inﬂammatory pathways (TNF-alpha and IL-1), such as those
induced by TLR423e25.
Signiﬁcant collagen depletion was observed in the cartilage of
MPS VI animals when compared with cartilage from healthy ani-
mals. In MPS VI rats the levels of collagen IIA1 and X are lower than
normal, and each was elevated in the treated by enzymeTable I
Osteoimmunological similarities between mucopolysaccharidoses and RA
Osteoimmunological similarities between MPS and RA
Elevated expression of inﬂammatory genes
Secretion of proinﬂammatory cytokines: TNF, IL-1
Secretion of NO (synoviocytes, chondrocytes)
Enhanced chondrocytes apoptosis
Reduced proteoglycan content
Up-regulation MMPs expression by proinﬂammatory cytokines
Enhanced expression and reduced efﬁciency of TIMP
Enhanced MMP activity
Exposure to abnormal mechanical forces
Elevated RANKL expression
Osteopenia
Increased osteoclastogenesis
Elevated levels of COX-2
Elevated STAT1 expression
MMP e matrix metalloproteinase.
References: 10,13,14,21,23,24,42.replacement therapy (ERT) or anti-TNF vs untreated MPS VI ani-
mals. Combined treatment ERT and anti-TNF led to greater collagen
IIA1 expression27. The increased chondrocyte apoptosis is thought
to be next reason for the diminished levels of proteoglycan and
collagen in articular cartilages15.
The important difference between MPS I and wild-type mice is
an increase in the amount of cartilage in the growth plates in MPS I
bones. The explanation may be augmented by a number of
cathepsin K-expressing osteoclasts in MPS I mice,
GAGs play an important role in the collagenolytic activity of
cathepsin K. GAGs predominantly expressed in bone and cartilage,
such as CS and KS, enhance the collagenolytic activity of CT K,
whereas DS, HS, and heparin selectively inhibit this activity26.
Wilson et al.28 demonstrated in murine MPS I that CT K expression
in bonewas signiﬁcantly increased over that inwildmice, but MPS I
mice revealed a signiﬁcant reduction in CT K-mediated cartilage
degradation in bones. One of the reasons for increased expression
of CT K can be increased activity of proinﬂammatory cytokines. An
important difference between MPS I and wild-type mice was an
increase in the amount of cartilage in the growth plates. These
results suggest that the accumulation of GAGs inmurineMPS I bone
has an inhibitory effect on CT K activity, resulting in impaired
osteoclast activity and decreased cartilage resorption28. These
processes are not fully understood. A recently published study
Chiaro et al.29 show reduced trabecular bone content and miner-
alization, signiﬁcantly increased cartilage area in bones and delayed
cartilage to bone conversion in MPS I dogs. Osteopenia has been
noted in the spines and long bones of skeletally mature MPS I dogs.
The alterations in the rate of chondrocyte maturation may be
affected by an increasingly inﬂammatory microenvironment,
particularly inhibition of chondrocytes differentiation and bones
growth by inﬂammatory cytokines. The inhibition of CT K may
other possible explanation for the slower removal of epiphyseal
cartilage in MPS I vertebrae29. Other recently published study on
MPS I mice by de Oliveira et al.30 suggests that progressive symp-
toms of MPS joint disease are characterized by bone and cartilage
resorption, mild inﬂammation and the progressive depletion of
collagen and proteoglycans, possibly caused by an up-regulation of
destructive proteases, such as MMP-2 and MMP-9. At 12 months of
age, bone resorption in 50% of MPS I mice was observed. The
measurement of growth plate width in MPS I mice did not show
signiﬁcant differences from age-matched controls.
Disorganized growth plates and abnormal cartilage were
described in human MPS I and IVA31e33 as well as in animals with
MPS VI27 and MPS VII34.
GAG accumulation in the growth plate decreased matrix depo-
sition, impaired chondrocytes and osteoblasts function, and disor-
dered growth plate cellular structure23e25,27,35. The MPS VI cat
growth plates compared with the normal animals exhibits poorly
organized zones, loss of column formation, an uneven chondro-
osseous junction and abnormal or reduced numbers of osteo-
clasts36. It results in irregularly shaped metaphyses, growth retar-
dation, thinning of bone trabeculae, and reduced body mass28.
In a recently published study Rowan et al.37 assessed severity of
bone disease among four MPS mouse models (MPS I, IIIA, IVA and
VII). MPS VII mice had the most severe bone pathology. The dif-
ferences between wild-type control mice and age-matched MPS I,
IIIA, and IVA mouse bone mineral density (BMDs) were not statis-
tically signiﬁcant. Severity of skeletal disease displayed by micro-
CT, radiographs and histopathology correlated with the level of
KS elevation in MPS I, IIIA, and VII mice. KS is accumulated only in
MPS IV patients, since the enzyme deﬁciency in MPS IV is involved
in the degradation pathway of KS. Themechanism of this secondary
KS elevation is not known. Rowan et al. studies suggest that KS
could be released from chondrocytes affected by accumulation of
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elevated in each type of examined non-type IV MPS.
Other MPS disease types: MPS VI and MPS VII primarily accu-
mulated DS show decrease in bone formation resulting in osteo-
penia28. In MPS VI and MPS VII only, the result of deﬁciency in
enzymes contributes to degradation of C4S34,37. The osteopenia
described in MPS VI and MPS VII is possible due to early chon-
drocyte death and decreased activity of osteoblasts. This could
result in incomplete endochondral ossiﬁcation and disorganization
of the growth plate. CT K may also be involved in the apparent
abnormal ossiﬁcation28.
The anthropometric features of patients and the body pro-
portions with all types of MPS are signiﬁcantly different from the
healthy population and differences increase with age.
Growth retardation might be minor in patients with attenuated
forms of the disease39e41. Similarly, in animals with MPS VI
impairment in longitudinal bone growth and vertebral body
growth compared to controls was observed42,43.
Impaired elastogenesis
The results of a study by Hinek A. et al. in MPS I suggest that DS
moieties bid to and cause functional inactivation of the elastin-
binding protein, a protective molecule for tropoelastin44. The
accumulation of DS (but not HS) by ﬁbroblasts leads to a disruption
of normal elastogenesis and leads to deﬁciency in elastic ﬁbers in
the skin, tendons, and cardiac valvular apparatus. The proper for-
mation of elastic ﬁbers is also an important factor in39maintaining
the proper shapes of normal embryonal skeleton and early skeletal
deformations in MPS I, II and VI may be associated with the
disorder42.
Osteoimmunological activation and impact on bone destruction in
MPS
Deforming arthropathy with bone destruction is a central
feature of skeletal system dysfunction in MPS I, II, III and VII45.It
reﬂects damage triggered by metabolic chronic inﬂammation.
Dysostosis multiplex reﬂects a destructive process in skeletal sys-
tem in imaging studies (Figs. 2 and 3).
The most characteristic bone changes in MPS I, II, VI and VII
include: macrocephaly, thickened skull, J-shaped sella turcica,
short, wide clavicles, wide oar shaped ribs, odontoid hypoplasia,
anterior beaking of the lower thoracic and upper lumbar vertebral
bodies, secondary thoracolumbar kyphosis, shortened long bones,
wide diaphyses, irregular metaphyses and narrow epiphyses,
bullet-shaped phalanges, proximal pointing of metacarpals and
metatarsals, ﬂattened acetabula, ﬂaring of iliac wings, coxa valga
deformity, dysplastic femoral heads, and secondary osteoarthritis,
genu valgum and secondary subtalar varus8.Fig. 2. A) and (B). Radiographs of pelvis from patients with JIA (A) and MPS VI (B). (A) Asym
erosions, and sclerosis of the right sacroiliac joint. Narrowing of hip joint space. (B) RoundRANK/RANKL/OPG pathway
RANK e receptor activator of NFkB (nuclear factor-kappa-B), a
member of TNF-alpha receptor member family, RANK ligand
(RANKL) and the osteoproteogerin (OPG), a decoy receptor of
RANKL regulate osteoclast differentiation and activity46.
Signiﬁcantly elevated RANKL gene expression was demon-
strated in chondrocytes, synoviocytes, and ﬁbroblast-like syno-
viocytes in MPS VI rats25.
Proinﬂammatory cytokines such as IL-1 and TNF-alpha are
potent stimulators of osteoclastic bone resorption through induc-
tion of RANKL expression and by activation receptors on the surface
of monocytes46.
Studies in animals with MPS VI and VII showed, that in the MPS
disorder, osteoclast precursors and other cells of macrophage
lineage might release proinﬂammatory cytokines and support
osteoclastogenesis, resulting in bone degradation and bone loss25.
Studies by Gatto et al. demonstrated that MPS I bone marrow
stem cells (BMSCs) displayed an increased capacity to support
osteoclastogenesis, which may correlate with the up-regulation of
the RANKL/RANK/OPG molecular pathway in MPS I BMSC
compared with normal BMSC47.The expansion rate and differenti-
ation capacity toward osteoblasts and chondrocytes of the MPS I
BMSC lines were similar to cells from normal control donors47.
Osteoclasts taken from MPS VII mice exhibit defective adhesion to
the bone matrix, a circumstance that likely interferes with normal
osteoclast function and bone remodeling because the cells must
adhere to the bone surface for resorption48.
TLR signaling pathway
Simonaro et al. studies revealed important role of TLR4 signaling
pathway inMPS and bone disease23. TLR4 signalingmay be induced
by lipopolysaccharides (LPS) or by, due to the structural similarity
to LPS, endogenous GAGs fragments. This activation resulted in the
synthesis and secretion of inﬂammatory mediators including:
chemokines (e.g., MIP-1a), cytokines (e.g., TNF-alpha and IL-1) and
products of proteolytic cascade (e.g., MMP e matrix
metalloproteinase).
An elevation in the expression of genes encoding TLR4, LBP (LPS
binding protein), MyD88 (myeloid differentiation factor-88), CXCR4
(chemokine receptor type 4), MIP-1a (Macrophage inﬂammatory
protein-1a) andmatrix metalloproteinase: MMP-1, MMP-2, MMP-9
and MMP-13 were found in the MPS VI and VII animals’ synovial
cells and cartilage. Increased expression of the CD44 adhesion re-
ceptor was detected in MPS VI rat synovial ﬁbroblasts and articular
chondrocytes, which is adequate for the activation TLR4 signal by
pathway speciﬁc for GAGs. And highly interesting, inactivation of
TLR4 in MPS VII mice had a signiﬁcant positive effect on their
growth, greater length of the bone, unchanged bone density,
improved growth plates, and normalization of TNF-alpha level23.metrical sacroiliac joint space: widening of the right space, irregularity, subchondrial
ed iliac wings, dysplastic femoral heads, severe hip dysplasia.
Fig. 3. A) and (B). Radiographs of hands from patients with JIA (A) and MPS VI (B). (A) Proximal interphalangeal (PIP) joint swelling (II P, II L, III L), contracture of PIP joints (V P),
Narrowing of metacarpophalangeal (MCP), PIP and wrist joints Spacesta. Joint destruction: geodes and erosions of MCP joints (III P, I P, III L), wrist (L and P), and radial-carpal joints
(L and P). (B) Claw hand deformity: bullet-shaped phalanges, thickened, short, metacarpal bones with proximal pointing and thin cortices, irregular carpal bones, irregular, broad
radial and ulnar epiphysis, distal interphalangeal joint contractures.
V. Opoka-Winiarska et al. / Osteoarthritis and Cartilage 21 (2013) 1813e1823 1817JAKeSTAT pathway
The Januskinaseesignal transducerandactivatorof transcription
(JAKeSTAT) pathway transmits information received from extra-
cellular polypeptide signals, through transmembrane receptors,
directly to target gene promoters in the nucleus, providing a
mechanism for transcriptional regulation. Many growth factors or
cytokines required tyrosine kinase (TYK) from the Janus kinase (JAK)
family for activity by receptor-associated cytoplasmic proteins. The
immediate responding genes are controlled by a family of
transcription-regulating signalingproteinsnamedsignal transducer
and activator of transcription (STAT)49. STAT1 is thought to have an
anti-proliferative effect on growth plate chondrocytes while STAT3
is believed tobe pro-proliferative in the growth plate34.Metcalf et al.
showed that reduction of chondrocyte proliferation and cell number
inMPSVII growthplates is associatedwith reduced levels of tyrosine
phosphorylated STAT3, which may reﬂect the reduced phosphory-
lation of TYK2, JAK1, and JAK2. Reduced activation of STAT3might be
a mechanism leading to reduced proliferation and shortened
bones34. In Simonaro study inactivation of the TLR4 pathway inMPS
VII mice corrected the abnormal pSTAT1 and pSTAT3 expression23.
Increased STAT1 expression is observed in patients with RA as
compared to osteoarthritis and reactive arthritis50.
Apoptosis
The apoptosis induced by accumulated GAG fragments might
play an important role in cartilage destruction and degenerative
joint disease in MPS I, II, VI and VII. An age-dependent increase in
articular chondrocyte apoptosis is observed in MPS VI animals15.
Inﬂammatory cytokines have a signiﬁcant impact on the increased
apoptosis of chondrocytes24. However, no signiﬁcant loss of their
numbers is observed, which is explained by increased expression of
TGF-b, an important growth factor of cell proliferation25.
Osteoimmunological impact on osteopenia in MPS
The most signiﬁcant ﬁnding in MPS VI bones is osteopenia with
fewer, thinner trabeculae. Osteoblast and osteoclast are vacuolated
with preserved function. Delayed ossiﬁcation is probably respon-
sible for the increased amounts of cartilage, where disturbances are
greater due to higher GAGs content than in bone51. Another
component of osteopenia in MPS VI appears to arise from a defect
in bone production due to a reduction in hypertrophic chon-
drocytes available for mineralization into bone25. In MPS disorder
the joints and bone tissue are inﬁltrated with proinﬂammatory
cytokineeproducing osteoclast precursors and other cells of the
macrophage lineage that release proinﬂammatory cytokines and
support osteoclastogenesis, resulting in chronic inﬂammation andbone loss. In MPS VI RANKL gene expression was signiﬁcantly
higher than in healthy animals. This inﬂammatory bone loss also
may lead to osteopenia23.
In a recent study conducted by Polgreen et al.52, children with
MPS I, II and VI had deﬁcits in BMD after adjustments for stature
and bone area. Additionally, short case reports in MPS III suggest
that BMD is diminished53. However, in the study of Fung et al. BMD
assessment in patients with MPS II and VI showed normal results54.
MPS patients with limited mobility and decreased physical ac-
tivity, are at increased risk for poor bone mineralization. Addi-
tionally, the presence of nutritional deﬁciencies, in particular
vitamin D deﬁciency, in this population may also negatively impact
bone accumulation54.
Biomarkers for bone and joint disease in MPS
Understanding the pathological processes in the osteoarticular
system can be used to objectively quantify the presence and clinical
progress of the disease. On the basis of recent study, primarily
in vitro and in vivo secondary biomarkers were identiﬁed for bone
and joint disease in MPS. These included proinﬂammatory cyto-
kines (TNF-alpha and IL-1) and metalloproteinases. These ﬁndings
have to be conﬁrmed in humans55.
The ongoing pathological process in the osteoarticular tissue of
patients with MPS is not completely understood, although broadly
conducted research explains the nature ofmany processes (Table II).
The processes described above are evidence that a signiﬁcant
component of MPS disorder is a systemic, chronic, inﬂammatory
disease of the connective tissue. These immunedisorders are similar
to those observed in many autoimmune diseases, the most to
rheumatic arthritis (Table I). The underlyingproblem is similare the
body’s immune system, designed to protect, becomes misdirected
and leads to inﬂammation. A normal self-limiting immune response
turns into a chronic process leading to damage.
In metabolic inﬂammation in MPS, the factor that causes an
immune process is known and it is an inborn metabolic error,
which causes the accumulation of GAGs and then immune
response. In classical autoimmune inﬂammation genetic risk fac-
tors are signiﬁcant, but the reason for the start of auto-
immunological processes is idiopathic. To start the process relevant
trigger factors, such as infections, environmental factors, chemicals
and other are probably required. In both cases, the immune process
lasts as long as the causing agent is present. In addition, the
generated damage is a source of inﬂammatory molecules.
Regardless of the beginning, in the later stages, inﬂammatory
process in theMPS and rheumatic diseases, especially RA, hasmany
common points (Table I). Elevated expression of inﬂammatory
Table II
Bone and cartilage abnormalities in MPS I, II and VI
Cell or tissue Morphology disorders Dysfunction
Chondrocyte - Enlarged cells
- GAG containing vacuoles
- Obscured organelle
- Deformed and displaced nucleus
- Enhanced apoptosis
- Reduced function
- Remain in immaturity, without changes in bone
- Proinﬂammatory cytokine release
- Increased nitric oxide production*
- Increased production of TNF*
- Increased production of IL-1b
Osteoclast - Vacuolated - Impaired function
- Defective adhesion to bone matrix
Osteoblast - Vacuolated - Impaired function
Synoviocyte/synovium - Hyperplastic - Increased proliferation of synoviocytes (hyperplasia)
- Enhanced MMPs activity
- Increased production of TNF
- Increased production of IL-1b
Growth plate cartilage - Higher amounts of undegraded GAGs
- Disturbed resting zone (increased height,
decreased extracellular matrix, enlarged cells)
- Disrupted columnar architecture
- Disturbed bone growth
- Increased expression of TGF-b
- Reduced osteonectin staining
- Impaired chondrocytes maturation and
transformation into bone
- Delayed turnover of hypertrophic chondrocytes
Articular cartilage - Thickened
- Matrix proteoglycans and collagen depletion
- Enhanced proliferation of chondrocytes
- Increased chondrocytes apoptosis
- Increased chondrocyte proliferation
- Increased secretion of proinﬂammatory cytokines
- Enhanced MMPs expression and activity
- Enhanced expression and reduced efﬁciency of TIMP-1
- Increased expression of TGF-b
- Impaired structure and function
- Reduced cathepsin K-mediated cartilage degradation
Bone - Osteopenia e decreased trabecular bone volume
- Thinner and fewer trabeculae
- Delayed ossiﬁcation
- Poor bone growth
Joint - Deformed destruction of the articular surfaces - Painful
- Poor mobility, stiffness, contractures
* Level signiﬁcantly greater in older animals compared with young and after GAG stimulation.
References: 14,21,23e27,39,43.
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both diseases. Up-regulation of MMPs expression by proin-
ﬂammatory cytokines with enhanced expression and reduced ef-
ﬁciency of tissue inhibitor of metalloproteinase (TIMP) cause
enhanced MMP activity and reduced proteoglycan content. The
secretion of proinﬂammatory cytokines TNF-alpha, IL-1 is associ-
ated with elevated RANKL expression, resulting in osteopenia56,57.
The next difference is the timewhen the immunological process
begins. TheMPSmetabolic inﬂammationbegins inearly in life and in
the natural course it progresses over the lifetime. The classical
autoimmuneprocess in an individualwith genetic risk factorsmight
start at a different age or in the absence of trigger factors did not
occur at all.
These differences result in different treatment strategies with
metabolic inﬂammation there are two possibilities: treatment by
removing the causative agent, aimed at reducing the accumulation
of GAGs, and the inhibition of secondary processes including anti-
inﬂammatory or immunosuppressive therapy (Table III). Due to its
unknown cause, in classical autoimmune inﬂammation, only
symptomatic treatment is possible, including anti-inﬂammatory or
immunosuppressive therapy. Similarity of inﬂammatory processes
in both types of diseases indicates the possibility of transferring the
experience with the treatment of rheumatic diseases to symptom-
atic therapy for MPS (Table III).
Present and future treatment options for osteoarticular
disorders in MPS
ERT and hematopoietic stem cell transplantation (HSCT)
At present, two types of causal therapy are available, which
reduce GAG accumulation: ERT currently available for patients withMPS I, II and VI, and HSCT recommended for young children with a
severe form of MPS I58. Unfortunately both have limited effects on
bones and joints.
The effectiveness of ERT is related to biodistribution of the
infused enzyme, which can easily reach reticuloendothelial organs
(e.g., liver, spleen), but to a smaller extent other organs and tissues
(e.g., articular cartilages) due to their poor vascular supply and the
difﬁculties in distribution to target cells in the matrix. Clinical trials
with ERT in MPS I, II, and VI show only slight or no improvement in
joint pain, stiffness, joint range of motion or hand dexterity. Skel-
etal changes are not reversed or stabilized by ERT2,59,60. However,
there is little or no evidence that ERT directly impacts cartilage and
bone disease in MPS patients. The effectiveness of treatment is
greater if it is introduced early in life61.
The positive effect of ERT is probably due to soft tissue changes
in the joints rather than direct delivery of the enzyme to the
cartilage or bone. ERT markedly reduces serum levels of TNF-alpha
and RANKL in MPS VI animals and therefore may have positive
secondary anti-inﬂammatory effects on other organs that are not
accessible to the enzyme, providing additional beneﬁts. ERT does
not reduce the synovial inﬂammation in MPS VI animals35.
Another study on animals with MPS VI shows that ERT can
prevent the vertebral and facial bone abnormalities, but cannot
reverse the deformations that have already occurred. ERT from
birth is effective at reducing the development of pathology in all
tissues examined except cartilage and cornea. Degenerative joint
changes are not delayed in treated animals, though skeletal pa-
thology is reduced, with more normalized bone dimensions and
with more uniform bone density and trabecular pattern62.
The limited use of HSCT is related to its potential side effects63.
Bonemarrow transplantation in MPS VI animals improves the bone
parameters (thickness and number of trabeculae)51, and restores
Table III
Therapy options for musculoskeletal changes in MPS disease
Therapy target in MPS Method Therapy recommended
in humans
Therapy in animal tests Other therapeutic options
Inborn gene defect Correction of a genetic defect Transfer the correct gene to
cells via viral vector
Genetic modiﬁcations of
animal cells
Modiﬁcation of cells with
genetic engineering to
augment enzyme production
Cells with enzyme defect Transplantation of hematopoietic
stem cells with correct enzyme
gene
HSCT (MPS I)
Umbilical cord blood
transplantation (UCBT)
HSCT (MPS II, III, VI,VI, VII)*
Misfolded protein
conformations of enzyme
resulting from mutations
Repair enzyme structure
Protection of enzyme against
degradation
ASSCs Active-site-speciﬁc chaperones
(ASSCs)*
Enzyme insufﬁciency Enzyme replacement ERT
(MPS I, II, VI)
Higher-dose intravenous ERT
Intra-articular ERT
ERT (MPS III, IV, VII)*
GAG intracellular and extracellular
storage
Substrate (GAGs) reduction Genistein (MPS III)*
Inﬂammation in musculoskeletal
system
Anti-inﬂammatory treatment NSAID
Physiotherapy
Anti-TNF
Anti-TNF þ ERT
Glucocorticoids
Anti-IL1y
Anti-TNFy
Inhibitor of the enzyme Janus
kinase 3 (JAK3)z
Osteoarticular destructions Inhibition of osteoarticular
destructions
Anti-TNF Anti-RANKLz
Anti-CD80/CD86 (CTLA 4)y
Anti-TNFy
Reduction weight bearing in
osteoarticular system
Kinesitherapy
Orthopedic devices
Orthopedic procedures
(joint replacement,
correction of the lower
limb axis)
* Treatment used in a small group of patients or in clinical trials for MPS.
y Therapy approved in humans for other diseases.
z Treatment used in patients in clinical trials for other diseases.
References: 2,22,29,47,48,52e59,61,62,65,67,68.
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derived from bone marrow, such as the growth plate, were not
improved.
Experience in MPS patients is limited to single published case
studies. HSCT does not correct skeletal deformities, despite
improving odontoid dysplasia and accelerating growth2. Many
patients receive immunosuppressant and steroid medication
following transplantation to protect against or alleviate graft-
versus-host disease and side effects outside the known (osteopo-
rosis, osteonecrosis). Secondary, anti-inﬂammatory beneﬁcial ef-
fects of the drugs on the osteoarticular system are possible. It
should be considered that the immunosuppressive drugs after
transplantation may have an anti-inﬂammatory effect on the
osteoarticular symptoms.
Small molecules
Active-site-speciﬁc chaperones (ASSCs) are enzyme active-site
directed small molecule pharmacological chaperones that in-
crease residual enzyme activity through the repair of misfolded
mutant proteins and protection against the endoplasmic reticulum-
associated degradation. ASSCs have been identiﬁed for MPS I, IV
and VII and currently are being evaluated in clinical trials in other
lysosomal storage diseases64.
Genistein (a compound from the group of isoﬂavones) therapy is
anotherexperimental option for treatmentofMPSpatients65e67. The
inhibitory effect of genistein on GAG synthesis and accumulation in
MPS cells is due to the inhibition of the kinase activity of the
epidermal growth factor (EGF) receptor and then expression of
particular genes that are regulated through EGF-dependent signaltransduction68. Slow GAG synthesis might prevent further accu-
mulationof these substances in apatient’s cells, and residual activity
of the deﬁcient enzymemaycause a reduction in the level of already
accumulated compounds and achievement of a new balance be-
tween GAG synthesis and degradation69. It is suggested that the
efﬁcacy of GET IT (Gene Expression-Targeted Isoﬂavone Therapy)
might be sufﬁciently high when using relatively high doses of syn-
thetic genistein rather than lowdoses of soy isoﬂavone extracts70,71.
The study of the effects of genistein therapy on joint function in
patients with MPS II is promising. In a study by Marucha et al.
administration of genistein-rich soy isoﬂavone extract in seven pa-
tients with MPS II resulted in improvement of connective tissue
elasticity, particularly range of joint motion in all cases72.
Anti-inﬂammatory treatment
Inﬂammatory processes in osteoarticular system in MPS disor-
der indicate the potential beneﬁts of anti-inﬂammatory treatment.
Because of the progressive nature of the disease, patients with
MPS require continuous therapy. Chronic administration of anti-
inﬂammatory drugs: nonsteroidal (NSAID), steroidal or cytotoxic
agents are limited due to side effects and should be used as short as
possible.
Currently in patients with MPS only NSAID and physiotherapy
are recommended for anti-inﬂammatory treatment15,73.
During prolonged use of NSAID side effects can be observed.
NSAIDs may cause gastrointestinal ulcers, serious cardiovascular
events, hypertension, acute renal failure, and worsening of preex-
isting heart failure. Those at risk for gastroduodenal ulcers may be
treated with concomitant proton-pump inhibitors, misoprostol
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cardiovascular events may be treated with naproxen and a proton-
pump inhibitor or misoprostol. These adverse effects may be pre-
vented by limiting NSAID dosage and duration and by performing
individual risk assessments74.
Therefore, an opportunity that is worth to consider in future
studies inMPS are biological drugs. Biological therapy has been very
successful in ameliorating symptoms of autoimmune disorders.
However, some side effects have been reported. For example, pa-
tients receiving anti-TNF regiments exhibit unexpected toxicities,
and anti-TNF therapymayenhance the risk of tuberculosis andother
infections. The epidemiological review of many clinical trials
involving anti-TNF therapy for RAdid notﬁnd any link between such
therapy and an increased risk of cancer, nevertheless, the potential
pro-oncogenic effect of anti-TNF therapy requires observations75.
Because of the importance of weight bearing in the induction of
osteoarticular inﬂammation, kinesitherapy, the use of additional
devices, and orthopedic procedures should be considered in every
patient with osteoarticular symptoms73,76.
Targeted biologic therapy
An understanding of inﬂammatory processes in MPS was a
reason for attempts to apply targeted biologic therapy. Over the
past decade, the introduction of targeted biologic therapy has
resulted in signiﬁcantly improved clinical and structural outcomes
for patients with RA and juvenile idiopathic arthritis (JIA). These
therapeutic agents have speciﬁc mechanisms of action, including
inhibiting the action of individual cytokines, blocking cellecell in-
teractions, and depleting certain cell types.
TNF-alpha is a dominant proinﬂammatory cytokine in the
pathophysiology of MPS and is the potential target of ﬁve biologic
agents actually approved to treat RA or JIA: adalimumab, certoli-
zumab pegol, etanercept, golimumab, and inﬂiximab.
Simonaro et al. evaluated the effects of anti-TNF-alpha (inﬂix-
imab) therapy in MPS VI rats. Early initiated treatment in the pre-
symptomatic period (at ﬁrst month of age) prevents the elevation
of TNF-alpha, RANKL and other inﬂammatory molecules in the
blood, articular chondrocytes and synovial ﬁbroblasts23. The
treatment of older animals (6 months old) also reduces the levels of
these molecules and earlier elevated levels of COX-2, TGF-b to
normal. The number of apoptotic articular chondrocytes in MPS VI
rats was signiﬁcantly reduced, did not differ from healthy animals,
and there was less invasion of the synovial tissue into the under-
lying bone. However, there was no effect on bone growth or clinical
improvement in motor activity with ERT alone35. Stored GAGs in
the growth plate are not reduced by anti-TNF treatment and mo-
lecular changes in this cartilage remain irreversible.
In Eliyahu et al. studies inMPS VI animals, the efﬁcacy of ERTand
combined treatment using ERT and anti-TNF drug was compared35.
Both protocols markedly reduced serum levels of TNF-alpha and
RANKL, although only combined treatment reduced TNF-alpha in
the articular cartilage. Analysis of cultured articular chondrocytes
showed that combination therapy restored collagen IIA1 expres-
sion and reduced expression of apoptotic markers. The synovial
membranes in untreated MPS VI animals were hyperplastic with
synovial villi. ERT did not reduce the synovial inﬂammation.
Combined therapy resulted in fewer villi, less inﬂammation, and
invasion of synovial tissue into underlying bone. Motor activity and
mobility were improved by ERT and signiﬁcantly enhanced by
combination treatment. Unfortunately micro-CT analysis of bone
and bone growth plates did not demonstrate any signiﬁcant posi-
tive effects from either treatment35.
Another proinﬂammatory cytokine signiﬁcantly elevated in
osteoarticular tissues in MPS is IL-1. Recombinant human IL-1Ra(IL-1 receptor antagonist), anakinra reduces the rate of radio-
graphic progression of RA and it is approved for RA treatment77. The
relevant role of IL-1 in the pathophysiology of MPS has been proven
and it might be, as anti-TNF, a future object for therapy23e25. The
drug has not been studied in MPS.
An antibody against RANKL, denosumab provides protection
from the progression of structural joint damage in RA patients.
Administration of denosumab to patients with RA in clinical trials
inhibited the development of structural damage, produced a sus-
tained decrease in markers of bone turnover, and resulted in
increased bone mineral density77,78. Because the participation of
RANKL in the pathogenesis of bone changes in MPS is well
demonstrated, the effectiveness of this therapy may be sus-
pected23e25.
An inhibitor of the enzyme Janus kinase 3 (JAK3), tofacitinib
interferes with the JAK-STAT signaling pathway, which transmits
extracellular information into the cell nucleus. In a model of
established arthritis, tofacitinib rapidly improved the disease by
inhibiting the production of inﬂammatory mediators and sup-
pressing STAT1-dependent genes in joint tissue79. The inhibition of
elevated expression STAT1 by tofacitinib in MPS can be another
potential therapy in the future.
The current studies suggest that anti-inﬂammatory action may
reduce the effects of GAG accumulation in osteoarticular system.
The use of different anti-inﬂammatory drugs, including biologic
agents require further study, but it seems to be an important di-
rection for new therapeutic options for patients with MPS.
Conclusions
1. Metabolic inﬂammation, secondary to GAG storage, is a sig-
niﬁcant cause of osteoarticular symptoms in MPS disorders I, II,
VI and VII.
2. MPS should be considered as a metabolic, systemic, and pro-
gressive inﬂammatory disease.
3. Currently available and/or recommended treatment options
are not sufﬁciently effective in prevention, inhibition, and
treatment of osteoarticular symptoms in MPS.
4. Better understanding of the osteoimmunological relationship
will result in development of new effective therapeutic stra-
tegies to treat MPS disease.
5. Inhibition of inﬂammation should be considered as a compo-
nent of MPS therapy.
6. Routine monitoring of MPS patients for inﬂammatory markers
other than CRP and ERS using laboratory tests should be
considered, especially when anti-inﬂammatory drugs are to be
included in the therapy, but also during the ERT.
7. Because similarities in the inﬂammatory process in RA andMPS
have been reported, experience with biological RA treatment
could be considered in MPS.
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